A Phase 2, single-arm study of bempegaldesleukin (NKTR-214) in combination with nivolumab in cisplatin ineligible, locally advanced or metastatic urothelial cancer patients
The purpose of this study is to study the effects, good and bad, of the study drug NKTR 214 in combination with nivolumab on participants and their urothelial cancer.
chemotherapy in cisplatin ineligible, locally advanced or
≥18 years old with metastatic urothelial or cisplatin ineligible urothelial carcinoma. Further labs, scans, and review of medical history will be done to confirm eligibility.
18 - 99
Healthy Volunteers Needed
Duration of Participation
For as long as the participant is seeing benefit from the study drug
Knight Cancer Institute Clinical Trials